NCT00203905View on ClinicalTrials.gov

A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2008

Conditions
Head and Neck Cancer
Interventions
DRUG

5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab

Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)

DRUG

5-Fluorouracil, Hydroxyurea-[FHX]

Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00203905 - A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck | Biotech Hunter | Biotech Hunter